Opencell Technologies and Adva Biotechnology: A Game-Changing Partnership
Opencell Technologies and Adva Biotechnology have announced a significant partnership aimed at revolutionizing cell and gene therapy manufacturing. This collaboration integrates Opencell's innovative Softporation™ technology with Adva's highly flexible automated manufacturing platform. The result is a comprehensive solution designed for the ever-evolving bioprocessing landscape.
The Essence of the Partnership
The partnership, structured as a non-exclusive commercial agreement, ensures that both companies maintain ownership of their respective intellectual properties. Adva will incorporate Opencell's Softporation™ technology as an optional feature within its advanced manufacturing platform. This collaboration represents a step forward in the production of cell therapies that are both efficient and patient-focused.
Transforming Manufacturing Processes
At the heart of this collaboration is the ADVA X3®, a state-of-the-art, fully automated platform that streamlines the manufacturing of cell therapies. This technology not only reduces costs but also guarantees the quality and availability of treatments for patients. By integrating the gentle, scalable Softporation™ technology into the ADVA X3® platform, the partnership aims to create a milestone in the cell and gene therapy sector.
Benefits for Patients and the Industry
The combination of these innovative technologies signifies a transformative advancement in the manufacturing of cell therapies. With an emphasis on scalability and cost-effectiveness, stakeholders within the industry will benefit from enhanced production capabilities, ultimately leading to better biological outcomes for patients.
Voices Behind the Partnership
“We are thrilled to collaborate with Adva Biotechnology,” said Dr. Behzad Mahdavi, Executive Chairman of Opencell Technologies. “This partnership aligns perfectly with our vision of providing a seamless and gentle solution that ensures superior outcomes for patients while fully leveraging Adva's technology.”
Innovation at the Forefront
Dr. Ohad Karnieli, CEO of Adva Biotechnology, echoed these sentiments, explaining that this partnership is a critical step toward delivering innovative solutions in the cell and gene therapy market. By incorporating Opencell's advanced Softporation™ system, Adva aims to meet the growing demands of their customer base with a cutting-edge, flexible solution.
About Opencell Technologies
Opencell Technologies is renowned for its bioprocess innovations, particularly in cell and gene therapy manufacturing. Through their proprietary Softporation™ technology, they offer a continuous transfection process that preserves cell health and supports multiple treatments. Their focus on enhancing manufacturing efficiency aims to improve therapeutic outcomes for patients globally.
About Adva Biotechnology
Adva Biotechnology is leading the charge in transforming cell therapy manufacturing. With their automated and controlled ADVA X3® platform, they aim to improve the quality and efficiency of advanced therapies. By incorporating artificial intelligence and biosensors, Adva seeks to enhance treatment options for various conditions, particularly cancer.
Frequently Asked Questions
What is the focus of the partnership between Opencell and Adva?
The partnership aims to integrate Opencell's Softporation™ technology with Adva's manufacturing platform to enhance cell and gene therapy processes.
What is Softporation™ technology?
Softporation™ is a gentle and scalable transfection process developed by Opencell Technologies, designed to maintain cell integrity during treatment.
How does the ADVA X3® platform improve manufacturing?
The ADVA X3® platform streamlines the cell therapy manufacturing process, reducing costs and ensuring high-quality therapy availability for patients.
What are the potential benefits of this partnership for patients?
This partnership aims to produce more effective therapies with enhanced scalability and cost-effectiveness, leading to better patient outcomes.
Who are the key executives involved in this collaboration?
Dr. Behzad Mahdavi of Opencell Technologies and Dr. Ohad Karnieli of Adva Biotechnology are pivotal in leading this innovative partnership.
